← Back to Search

Other

INCB086550 for Solid Tumors

Phase 1

Waitlist Available

Research Sponsored by Incyte Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up every 8 weeks for the duration of study participation; estimated to be 12 months.

Awards & highlights

Study Summary

This trial is testing a new drug for people with advanced cancer who have already tried other treatments. They want to see if it is safe and if it works.

Eligible Conditions

Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ every 8 weeks for the duration of study participation; estimated to be 12 months.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~every 8 weeks for the duration of study participation; estimated to be 12 months.

This trial's timeline: 3 weeks for screening, Varies for treatment, and every 8 weeks for the duration of study participation; estimated to be 12 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of treatment-emergent adverse events

Secondary outcome measures

AUC 0-t and/or AUC0-∞ of INCB086550 in fasted and food effect conditions

AUC0-tau of INCB086550 in fasted and food effect conditions

CL/F of INCB086550

+10 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: INCB086550Experimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

INCB086550

2022

Completed Phase 1

~150

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor

364 Previous Clinical Trials

55,027 Total Patients Enrolled

Kevin O'Hayer, MD, PhDStudy DirectorIncyte Corporation

Media Library

INCB086550 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03762447 — Phase 1

Solid Tumors Research Study Groups: INCB086550

Solid Tumors Clinical Trial 2023: INCB086550 Highlights & Side Effects. Trial Name: NCT03762447 — Phase 1

INCB086550 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03762447 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are volunteers still being recruited for this clinical experiment?

"This investigation, which was first placed on December 10th 2018 and last updated June 24th 2022, is not currently recruiting. However, there are an abundance of other medical studies seeking participants at this time - 2584 to be exact."

Answered by AI

What potential dangers could be associated with taking INCB086550?

"There is a small amount of evidence that indicates the safety and efficacy of INCB086550, so it received a score 1 on our team's scale."

Answered by AI

How many research locations are currently conducting this investigation in the city?

"Currently, 8 medical centres are signing up participants for this trial. The list of hospitals includes Jefferson University Hospitals in Philadelphia, the University of Pennsylvania Health System in Tampa and H. Lee Moffitt Cancer Center and Research Institute Hospital in Washington to name a few out of these eight locations."

Answered by AI

Recent research and studies

Cancer DiscoveryJournal

Characterization of INCB086550: A Potent and Novel Small-molecule PD-L1 Inhibitor

Koblish, Holly K., Liangxing Wu, Liang-Chuan S. Wang, Phillip C.C. Liu, Richard Wynn, Jonathan Rios-Doria, Susan Spitz, et al.. 2022. “Characterization of INCB086550: A Potent and Novel Small-molecule PD-L1 Inhibitor”. Cancer Discovery. American Association for Cancer Research (AACR). doi:10.1158/2159-8290.cd-21-1156.

clinicaltrials.govStudy

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

2018. "A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03762447.